Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

-list item one, The purpose of this study is to evaluate the overall response rate of belotecan (CKD-602) in recurrent or progressive carcinoma of uterine cervix

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sokbom Kang
• Treatments: Belotecan; Camptothecin

Criteria

Inclusion Criteria:

• Histologically confirmed, patients with recurrent uterine cervical carcinoma who were unsuitable candidates for curative treatment with surgery and/or radiotherapy.

• One of the following histologic types

• Squamous cell carcinoma

• Adenocarcinoma

• Adenosquamous carcinoma

• Clinically measurable disease

• Performance status of 0, 1, 2 on the ECOG criteria

Exclusion Criteria:

• Histology of neuroendocrine tumors

• Patient previously treated with topoisomerase-I inhibitor